Related references
Note: Only part of the references are listed.The Expiry of Humira(R) Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
Evelien Moorkens et al.
FRONTIERS IN PHARMACOLOGY (2021)
Evaluation of Adherence and Persistence Differences Between Adalimumab Citrate-Free and Citrate Formulations for Patients with Immune-Mediated Diseases in the United States
Martin Bergman et al.
RHEUMATOLOGY AND THERAPY (2021)
Does Similarity Breed Contempt? A Review of the Use of Biosimilars in Inflammatory Bowel Disease
Shubha Bhat et al.
DIGESTIVE DISEASES AND SCIENCES (2021)
Biosimilars in Inflammatory Bowel Disease
Anna M. Buchner et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2021)
AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis
J. Hercogova et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre
Martin Lukas et al.
JOURNAL OF CROHNS & COLITIS (2020)
Understanding and Minimising Injection-Site Pain Following Subcutaneous Administration of Biologics: A Narrative Review
Anja St Clair-Jones et al.
RHEUMATOLOGY AND THERAPY (2020)
Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study
Piotr Wiland et al.
BIODRUGS (2020)
Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence
Salvatore Bellinvia et al.
BIODRUGS (2019)
Changes in inflammatory bowel disease patients' perspectives on biosimilars: A follow-up survey
Laurent Peyrin-Biroulet et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2019)
Biosimilars of adalimumab: the upcoming challenge in IBD
Gionata Fiorino et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2019)
Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis
Michael E. Weinblatt et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
Sizheng Zhao et al.
CURRENT RHEUMATOLOGY REPORTS (2018)
Biosimilars in IBD: from theory to practice
Silvio Danese et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2017)
Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany
Emma Sullivan et al.
PLOS ONE (2017)
Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK
Mohammed I. Aladul et al.
BIODRUGS (2017)
Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases
N. Mitrev et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study
Stanley Cohen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
A Critical Review of Biosimilars in IBD: The Confluence of Biologic Drug Development, Regulatory Requirements, Clinical Outcomes, and Big Business
Christina Y. Ha et al.
INFLAMMATORY BOWEL DISEASES (2016)
Changes in Biosimilar Knowledge among European Crohn's Colitis Organization [ECCO] Members: An Updated Survey
Silvio Danese et al.
JOURNAL OF CROHNS & COLITIS (2016)
Share Paper
